SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock price jumped following news that CEO Elon Musk purchased a significant amount of shares, his first open-market buy since 2020. The community is discussing whether this purchase signals a short squeeze to $500 and how it impacts the stock's technical analysis. Many view this as a bullish sign, while some remain skeptical, citing concerns about valuation and Musk's overall strategy.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to a recent surge following positive trial results for its stroke therapy, with community members debating whether to hold for a potential FDA submission catalyst or take profits amidst concerns of manipulation and past reverse splits. The stock's low float is fueling discussions about a potential short squeeze, while some caution against a possible offering. The community is closely watching for news that could drive the price higher, as well as the company's next move.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around ATYR as traders await the release of Phase 3 trial data, expected mid-September, with the community buzzing about potential data leaks and speculating on the timing of the results. Community members are weighing bullish and bearish perspectives, debating the likelihood of trial success, and analyzing the potential for a short squeeze. With a binary event on the horizon, ATYR is seeing increased volatility and high options premiums, driving significant conversation among investors.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies behind the project's resilience and upcoming developments, including a Bifinance listing and airdrop. Community members highlight the project's organic growth, transparency, and active development team. Bullish sentiment is high, with many anticipating new ATHs and increased exposure for this Solana-based token.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending due to its recent merger with Strive and a planned pivot towards Bitcoin asset management, creating excitement around a potential short squeeze. Some platforms are experiencing trading halts due to the CUSIP change, while community members debate holding strategies amidst high short interest and borrow fees. The stock's association with figures like Vivek Ramaswamy is also fueling speculation and interest.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to Needham's raised price target and overall excitement in the quantum computing sector, sparking discussions about its potential and possible acquisitions. Community members debate the company's valuation, long-term prospects, and potential to become the "next NVDA", while also discussing upcoming catalysts like the analyst day and potential government contracts. The stock's breakout and trading volume are also contributing to the increased attention.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as retail investors anticipate new peaks, with community members actively discussing potential price movements and key resistance levels. The stock is also gaining attention due to its participation in the White House's eVTOL pilot program and speculation around defense contracts. Community sentiment suggests anticipation for a potential squeeze, with some expressing frustration over the stock's performance compared to sector peers.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab ($RKLB) is trending due to positive momentum, with the stock hitting new 52-week highs and breaking through resistance levels, fueling bullish sentiment. The community is discussing potential for further gains, eyeing targets like $60 and beyond, driven by the anticipation around the Neutron rocket and recent mission successes. Some are noting increased call option activity and institutional investment as potential drivers for continued upward movement.

Investment Managers Series Trust II - Tradr 2X Short TSLA Daily ETF

Tradr 2X Short TSLA Daily ETF

TSLQ is trending as traders discuss potential downside for Tesla (TSLA) amid ongoing debate around its valuation, sales, and the impact of Elon Musk's actions. Community members are actively strategizing entry points and discussing potential profit targets, considering both technical analysis and broader market sentiment. Some traders mention potential short-term gains while others suggest Tesla fundamentals do not justify the current market value.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss the potential impact of a recent real-world tragedy, with some speculating it could drive increased traffic to the platform amid broader conversations around free speech. Community members are also weighing in on the company's fundamentals, potential catalysts like the upcoming wallet launch, and the proposed acquisition of Northern Data. Additionally, there's discussion around the high short interest and its potential to fuel a squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apellis Pharmaceuticals is drawing renewed attention from short sellers even as its stock extends a rebound sparked by better-than-expected&nbsp;bottom-line results.Short interest as a percentage of free float rose to 21.1% last week, the highest in three weeks, after bottoming near 21% in late July, according to Ortex data compiled by The Fly.&nbsp;Days-to-cover climbed to 2.8 from 2.6, although volumes stayed heavy following the earnings release, limiting further upside pressure.Shares gained 13.5% in the five sessions through Thursday and have now rallied 45% since July 31, when Apellis reported a second-quarter loss of $0.33 per share, narrower than&nbsp;analysts’ expectations.&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> rose 0.5% on Friday to close at $27.75, its highest level in six months, extending a four-session winning streak.Revenue of $178.5 million missed consensus by about $10 million, but investors cheered the earnings surprise along with regulatory and business updates.&nbsp;Quarterly sales were driven by $151 million from Syfovre, its treatment for geographic atrophy, and $21 million from Empaveli for paroxysmal nocturnal hemoglobinuria. Apellis also secured FDA approval of Empaveli for rare kidney diseases C3G and primary IC-MPGN, the first approved therapies for these conditions.Additionally, Apellis signed a capped royalty deal with Sobi worth up to $300 million for ex-U.S. Aspaveli sales and ended June with $370 million in cash.&nbsp;The company said the combination of cash, the Sobi payment, and future revenues should be sufficient to fund operations to profitability.Following the quarterly results, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-buzz-surges-for-apellis-as-goldman-hikes-price-target-after-solid-syfovre-sales-fda-win-for-kidney-drug/chr3ZbiRdGS">raised its price target</a> to $26 from $24, citing strong quarterly execution and long-term potential across its complement-focused pipeline.&nbsp;Citi lifted its target to $46 from $41, calling Empaveli “best-in-class,” while Scotiabank raised its target to $22 on confidence in launch execution. Baird, BofA, and Morgan Stanley also issued upward revisions earlier in August, reflecting improving sentiment.Despite the rebound, the pickup in short positioning suggests some investors expect profit-taking after the momentum-driven surge.On Stocktwits, retail sentiment for Apellis&nbsp;remained ‘bearish’ amid ‘extremely low’ message volume.Apellis’ stock has declined 13% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

APLS stock has declined 13% so far in 2025. (Photo credit: Getty Images)

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary

Apellis stock has surged since its earnings, but rising short interest suggests some investors are betting on profit-taking.

Equity

Retail chatter around Apellis Pharmaceuticals spiked Thursday after Goldman Sachs raised its price target to $26 from $24, citing strong quarterly performance and long-term growth potential through its pipeline of immune system therapies.Goldman’s move came on the heels of Apellis’ second-quarter earnings report, which showed total revenue of $178 million.&nbsp;Syfovre, the company’s treatment for geographic atrophy,&nbsp;generated $151 million in U.S. net product sales,&nbsp;representing a 6% quarter-over-quarter&nbsp;increase in injection volume. Despite a $13 million revenue impact due to increased free sample usage linked to co-pay assistance constraints, the product maintained a dominant market position with over 60% share of new GA patient starts.&nbsp;Empaveli contributed $20.8 million in sales, supported by high compliance rates.The FDA’s recent approval of Empaveli for patients aged 12 and older with C3G and IC-MPGN added another major catalyst. Backed by Phase 3 Valiant trial data, the decision cleared the way for Empaveli’s use in two rare kidney diseases that impact approximately 5,000 patients in the U.S.&nbsp;The trial showed a 68% drop in urinary protein levels, steady kidney function, and clearance of C3 deposits, which are key indicators of kidney health. The label also includes patients with post-transplant recurrence of C3G.Analyst sentiment has improved notably in recent weeks. Citi raised its price target to $46 from $41, calling Empaveli “best-in-class” and a potential growth driver. Scotiabank lifted its target to $22, highlighting confidence in the company’s ability to execute on the Empaveli launch. Baird, BofA, and Morgan Stanley also issued upward revisions earlier this month.Apellis also strengthened its balance sheet through a $300 million royalty agreement with Sobi, selling 90% of future ex-U.S. royalties on Aspaveli, the ex-U.S. brand of Empaveli, for $275 million upfront.&nbsp;The deal includes a $25 million milestone tied to potential EMA approval for the new kidney indications later this year.On Stocktwits, retail sentiment was ‘extremely bullish’ late Thursday amid a 72% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 32.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Apellis Pharmaceuticals (APLS) spiked Thursday after Goldman Sachs raised its price target to $26 from $24. (Photo credit: Getty Images)

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug

Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from co-pay assistance constraints.

Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Repligen (RGEN) Lags Q2 Earnings Estimates

Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Retail buzz around Apellis Pharmaceuticals&nbsp;intensified on Monday after the FDA approved Empaveli,&nbsp;clearing the way for its use in treating two rare kidney diseases that often lead to kidney failure.&nbsp;The drug is now approved for patients 12 and older with C3G and IC-MPGN, which are conditions that affect 5,000 people in the U.S.&nbsp;The decision was backed by data from the Phase 3 Valiant trial, where patients on Empaveli saw a 68% drop in protein levels in their urine, a key sign of kidney stress, along with steady kidney function and signs that harmful C3 deposits were being cleared.&nbsp;The label also includes patients with post-transplant recurrence of C3G.The FDA decision comes amid a flurry of Wall Street updates on Apellis. Earlier this month, Baird raised its price target on Apellis to $50 from $47, updating its model ahead of second-quarter earnings and noting competitive developments in the C3G space.Morgan Stanley and BofA also raised their price targets, now at $26 and $24, respectively.&nbsp;BofA maintained a ‘Neutral’ rating and noted that Apellis has not provided sales guidance for Syfovre, its treatment for geographic atrophy. Morgan Stanley maintained an ‘Equal Weight’ rating and cited the royalty purchase agreement with Sobi.Apellis recently struck a $300 million royalty deal with Sobi, selling 90% of its future ex-U.S. royalties from Aspaveli, its treatment for a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), to strengthen its cash position.Apellis will receive $275 million upfront and may earn another $25 million if Aspaveli is approved for C3G and IC-MPGN in Europe.On Stocktwits, retail sentiment for Apellis was ‘extremely bullish’ amid a 2,350% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 43.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals 

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest APLS News

APLS Apellis Pharmaceuticals Inc